Qual é o preço para Artiva Biotherapeutics, Inc. (ARTV)

O preço para Artiva Biotherapeutics, Inc. (ARTV) é $11.09

Qual é a capitalização de mercado para Artiva Biotherapeutics, Inc. (ARTV)

A capitalização de mercado para Artiva Biotherapeutics, Inc. (ARTV) é $542.19M

Artiva Biotherapeutics, Inc. (ARTV) Índice P/V

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Ano	Rácio P/S	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Rácio P/S

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rácio P/S	Diferença do rácio P/S	País
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

Empresa

Rácio P/S

Diferença do rácio P/S

País